May 30, 2023

Healey-Driscoll Administration and Massachusetts Life Sciences Center Announce $24.4 Million Job Creation Incentives for 43 Massachusetts Life Sciences Companies

Incentives expected to create nearly 1,600 life sciences jobs throughout Massachusetts; Since MLSC’s inception, Tax Incentive Program has helped create more than 11,000 jobs

Today, during an event at Moderna’s clinical manufacturing facility in Norwood, the Healey-Driscoll Administration and Massachusetts Life Sciences Center (MLSC) announced $24.4 million in tax incentive awards to 43 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,584 new life sciences industry jobs in the Commonwealth.  

The MLSC Tax Incentive program is offered to companies engaged in life sciences research and development, commercialization, and manufacturing in Massachusetts, providing incentives to companies of all sizes looking to expand their efforts by creating new, long-term jobs in the state. 

“Massachusetts is a global leader in the life sciences sector thanks to companies like Moderna and the dozens of others that will benefit from these tax incentive awards,” said Governor Maura Healey. “This funding will support cutting-edge research, advance the manufacturing of life-changing therapies, create thousands of jobs for companies across the state, and strengthen our position as the best place in the world to grow a life sciences company.” 

“Our administration works every day to help companies start, grow, and stay here in Massachusetts,” said Economic Development Secretary Yvonne Hao, who also serves as co-chair of the MLSC Board of Directors. “We are excited to see how today’s investments help life sciences companies expand their operations across the state and are grateful to Governor Healey and Lt. Governor Driscoll for their commitment to lengthening our lead as a life sciences hub through this funding.”  

Out of the 43 companies receiving tax incentive awards, 26 companies—accounting for 69 percent of the new jobs—are expanding outside of Boston and Cambridge. Since the MLSC’s reauthorization in 2018, 78 percent of jobs committed through the MLSC’s Tax Incentive program are located outside of Boston and Cambridge. Since the Center’s inception, life sciences companies expanding across Massachusetts have committed to the creation of more than 11,000 jobs through this program. 

“The Life Sciences Center will continue to deploy every resource necessary to support life science companies of all sizes and sub-sectors,” said MLSC President and CEO Kenn Turner. “I am grateful for the support of the Healey Administration and legislative leaders who understand the power of public-private partnership to drive economic and workforce development. I am equally excited for the growth of our companies being celebrated today as they work to produce life-saving therapies and products for patients on a global scale.” 

This year’s Tax Incentive Program award recipients represent a diverse cohort of companies working on drug discovery and development, medical devices, diagnostics, and manufacturing. The recipients include: 

Company Expansion Location Incentive Amount Jobs Commitment 
Access Vascular Inc. Billerica $180,000  12 
Aera Therapeutics Inc. Boston $450,000  30 
Affini-T Therapeutics Inc. Watertown $375,000  25 
Agilent Technologies Inc. Chicopee $150,000  10 
Ascidian Therapeutics Inc. Boston $180,000  12 
Berkshire Sterile Manufacturing Lee $225,000  15 
Bristol-Myers Squibb Company Boston/Devens $1,155,000  77 
Charles River Laboratories Inc. Wilmington $1,470,000  98 
Corner Therapeutics Inc. Watertown $150,000  10 
Day Zero Diagnostics Inc. Boston $225,000  15 
Disc Medicine Inc. Watertown $150,000  10 
ElevateBio Technologies Inc. Waltham $600,000  40 
Eli Lilly and Company Boston $494,000  26 
Enanta Pharmaceuticals Inc. Watertown $150,000  10 
Entegris Inc. Billerica $750,000  50 
Instrumentation Laboratory Company Bedford $255,000  17 
Intellia Therapeutics Cambridge $1,275,000  85 
Lonza Biologics Inc. Cambridge $165,000  11 
Lyra Therapeutics Inc. Watertown $300,000  20 
Manifold Bio Boston $150,000  10 
Matchpoint Therapeutics Inc. Cambridge $165,000  11 
Mersana Therapeutics Inc. Cambridge $150,000  10 
Miltenyi Biotec Inc. Cambridge $195,000  13 
ModernaTX Inc. Norwood $3,135,000  209 
ModeX Therapeutics Inc. Natick $525,000  35 
MOMA Therapeutics Inc. Cambridge $195,000  13 
Nova Biomedical Corporation Waltham $1,125,000  75 
Optikos Corporation Wakefield $180,000  12 
PGN US Holding, Inc. and Subsidiaries Burlington $150,000  10 
Prime Medicine Inc. Boston $750,000  50 
Rentschler BioPharma Inc. Milford $825,000  55 
Sarepta Therapeutics Inc. Cambridge $1,500,000  100 
Seismic Therapeutic Inc. Cambridge $150,000  10 
Snapdragon Chemistry Inc. Waltham $150,000  10 
Strand Therapeutics Boston $600,000  40 
Takeda Pharmaceuticals America Inc.  Lexington $1,875,000  125 
Tessera Therapeutics, Inc. Sommerville $1,125,000  75 
Tome Biosciences Inc. Watertown $750,000  50 
Treeline Biosciences Inc. Watertown $225,000  15 
Trelleborg Sealing Solutions US Inc.  Northborough $150,000  10 
Vaxess Technologies Inc. Cambridge $270,000  18 
Vedanta Biosciences Cambridge $450,000  30 
WuXi Biologics USA LLC Worcester $1,000,000  25 

The MLSC jointly administers the Tax Incentive Program with the Massachusetts Department of Revenue (DOR), which oversees the technical administration of the incentives. Awardees are required to maintain job commitments over a five-year period. The program includes regular reporting requirements for awardees to document jobs created as a result of the incentive. MLSC has continued to use the Tax Incentive Program to leverage diverse life sciences assets across Massachusetts and encourage growth and expansion on a statewide basis.